Akeso's Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Study

Key Facts

In a move reflecting the intensifying competition within the innovative biopharmaceutical sector, Akeso, a partner of Summit Therapeutics, has achieved a significant clinical milestone. The company reported positive overall survival results for its drug ivonescimab in a Phase 3 clinical trial for lung cancer patients. According to reports, ivonescimab demonstrated superior efficacy compared to Merck's Keytruda, signaling its potential to redefine the standard of care in oncology.

These clinical results strengthen Akeso's position against major global competitors in the oncology market. Per market data, the company's stock (9926.HK) closed at HKD 87.8 on September 2, 2026, having reached a day high of HKD 88.2. Outperforming a dominant treatment like Keytruda is a major milestone for a mid-cap biotech partner, potentially impacting future market share dynamics.

Traders are watching for the stock to maintain levels above the HKD 85.55 support established at the close of September 2, 2026. While the upcoming economic calendar shows no direct catalysts for the biotech sector, broader sentiment in Hong Kong-listed healthcare stocks may continue to react to the outcomes of the recently concluded National People's Congress in China.